TAS2R16

Across TCGA pan-cancer cohorts, TAS2R16 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated TAS2R16 data layer compared with 2 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TAS2R16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, COAD, and UCEC are the cancer types where TAS2R16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	30	view →
COAD	OS	Median	All	0.450	0.870	<.001	21	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.025	20	view →
OV	DFS	Median	II,III,IV	0.223	0.541	.041	18	view →
BLCA	OS	Median	All	0.141	0.687	.003	18	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →
SKCM	OS	Median	All	0.134	0.329	.008	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TAS2R16–SCLC (OS)

Open the SCLC breakdown →